Literature DB >> 10947683

The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology.

W Haverkamp, G Breithardt, A J Camm, M J Janse, M R Rosen, C Antzelevitch, D Escande, M Franz, M Malik, A Moss, R Shah.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10947683     DOI： 10.1016/s0008-6363(00)00119-x

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN： 0008-6363            Impact factor:   10.787


× No keyword cloud information.
  68 in total

1.  ISHNE guidelines for electrocardiographic evaluation of drug-related QT prolongation and other alterations in ventricular repolarization: task force summary. A report of the Task Force of the International Society for Holter and Noninvasive Electrocardiology (ISHNE), Committee on Ventricular Repolarization.

Authors:  A J Moss; W Zareba; J Benhorin; J P Couderc; H Kennedy; E Locati-Heilbron; P Maison-Blanche
Journal:  Ann Noninvasive Electrocardiol       Date:  2001-10       Impact factor: 1.468

2.  New era for digital ECG: FDA requires digital ECG submission for tested drugs.

Authors:  Wojciech Zareba
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-01       Impact factor: 1.468

3.  Computer-based analysis of dynamic QT changes: toward high precision and individual rate correction.

Authors:  Corina Dota; Bo Skallefell; Nils Edvardsson; Gunnar Fager
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-10       Impact factor: 1.468

Review 4.  Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

Authors:  Candace S Brown; Richard G Farmer; Judith E Soberman; Samantha F Eichner
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 5.  Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy.

Authors:  Joanna M Brell
Journal:  Prog Cardiovasc Dis       Date:  2010 Sep-Oct       Impact factor: 8.194

Review 6.  Drug-induced long QT syndrome.

Authors:  Prince Kannankeril; Dan M Roden; Dawood Darbar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 7.  Primary prevention of sudden cardiac death.

Authors:  Paulus Kirchhof; Günter Breithardt; Lars Eckardt
Journal:  Heart       Date:  2006-12       Impact factor: 5.994

8.  Azithromycin Causes a Novel Proarrhythmic Syndrome.

Authors:  Zhenjiang Yang; Joseph K Prinsen; Kevin R Bersell; Wangzhen Shen; Liudmila Yermalitskaya; Tatiana Sidorova; Paula B Luis; Lynn Hall; Wei Zhang; Liping Du; Ginger Milne; Patrick Tucker; Alfred L George; Courtney M Campbell; Robert A Pickett; Christian M Shaffer; Nagesh Chopra; Tao Yang; Bjorn C Knollmann; Dan M Roden; Katherine T Murray
Journal:  Circ Arrhythm Electrophysiol       Date:  2017-04

9.  Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.

Authors:  James T Milnes; Olivia Crociani; Annarosa Arcangeli; Jules C Hancox; Harry J Witchel
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

10.  Sildenafil citrate does not affect QT intervals and QT dispersion: an important observation for drug safety.

Authors:  Mete Alpaslan; Ersel Onrat; Murat Samli; Cetin Dincel
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-01       Impact factor: 1.468
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.